AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25042022 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental exposure to cigarette smoke (group 1)
Number of subjects: 39
Study 25042022 — intervention group
Group type: COMPARATOR
Intervention: No environmental exposure to cigarette smoke (group 2)
Number of subjects: 39
Study 22324058 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration + exercise
Number of subjects: 77
Study 22324058 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 77
Study 20541986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral support exercise
Number of subjects: 134
Study 20541986 — intervention group
Group type: COMPARATOR
Intervention: Typical introductory methods exercise
Number of subjects: 134
Study 18689718 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisin (6 microg/mL) applied to the nipple and mammary areola for 2 weeks
Number of subjects: 8
Study 18689718 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar preparation devoid of nisin)
Number of subjects: 8
Study 16708816 — intervention group
Group type: EXPERIMENTAL
Intervention: Harnal (0.2 mg/d)
Number of subjects: 222
Study 16708816 — intervention group
Group type: EXPERIMENTAL
Intervention: Proscar (5 mg/d)
Number of subjects: 222
Study 16708816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 222
Study 12778355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy according to AML-BFM 93 protocol
Number of subjects: 471
Study 12778355 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem-cell transplantation in first remission
Number of subjects: 471
Study 10388332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food for Heart Program (nutrition counseling for public health nurses)
Number of subjects: 468
Study 7733839 — intervention group
Group type: EXPERIMENTAL
Intervention: Levorotatory form of 5-hydroxytryptophan
Number of subjects: 26
Study 7733839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2252527 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone (15 mg/day)
Number of subjects: 25
Study 2252527 — intervention group
Group type: COMPARATOR
Intervention: indomethacin (100 mg/day)
Number of subjects: 25
Study 2252527 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 6994638 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 90
Study 6994638 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 90
Study 31775065 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto program
Number of subjects: 3298
Study 31775065 — intervention group
Group type: COMPARATOR
Intervention: Baseline risk factors (sociodemographic characteristics, school experiences, social variables)
Number of subjects: 3298
Study 31344077 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 different simulation sessions over 1 year
Number of subjects: 48
Study 31344077 — intervention group
Group type: COMPARATOR
Intervention: 3 simulation sessions (initial, intermediate after 6 months, final after 1 year)
Number of subjects: 48
Study 28504569 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended essential oil (1:1:1 ratio of L. angustifolia, Salvia sclarea, and Origanum majorana)
Number of subjects: 132
Study 28504569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure massage
Number of subjects: 132
Study 28504569 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil (Lavandula angustifolia)
Number of subjects: 132
Study 28504569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 132
Study 26288888 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable camera system
Number of subjects: 9
Study 23443360 — intervention group
Group type: EXPERIMENTAL
Intervention: THC administration
Number of subjects: 21
Study 23443360 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 21
Study 21075015 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection at MSKCC (91 patients)
Number of subjects: 261
Study 21075015 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection at FALP (33 patients)
Number of subjects: 261
Study 21075015 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection at YCU (36 patients)
Number of subjects: 261
Study 21075015 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated at FALP
Number of subjects: 261
Study 21075015 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated at YCU
Number of subjects: 261
Study 21075015 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated at MSKCC and YCU
Number of subjects: 261
Study 21075015 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 261
Study 19705105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (sedating antihistamine)
Number of subjects: 15
Study 19705105 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine (nonsedating antihistamine)
Number of subjects: 15
Study 19705105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17894263 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent health promotion program
Number of subjects: 266
Study 17894263 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 266
Study 15052246 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified QGS software used in patients with angina pectoris (AP)
Number of subjects: 81
Study 15052246 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified QGS software used in patients with old myocardial infarction (MI)
Number of subjects: 81
Study 15052246 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 81
Study 11712038 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aspirin/dichloromethane solution
Number of subjects: 29
Study 11712038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9131458 — intervention group
Group type: EXPERIMENTAL
Intervention: PMK‐OPV
Number of subjects: 21
Study 9131458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero‐OPV
Number of subjects: 21
Study 7924704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileoanal reservoir procedure in patients over the age of 50 years (Group I)
Number of subjects: 72
Study 7924704 — intervention group
Group type: COMPARATOR
Intervention: Ileoanal reservoir procedure in patients under the age of 50 years (Group II)
Number of subjects: 72
Study 3344578 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation of the puncture needle by 90 degrees
Number of subjects: 20
Study 3344578 — intervention group
Group type: COMPARATOR
Intervention: Conventional lumbar puncture
Number of subjects: 20
Study 30323393 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients dressed in moulage
Number of subjects: 0
Study 30323393 — intervention group
Group type: COMPARATOR
Intervention: Picture-based paper cases
Number of subjects: 0
Study 27789188 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg AMG 747
Number of subjects: 232
Study 27789188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 27789188 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg AMG 747
Number of subjects: 232
Study 27789188 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg AMG 747
Number of subjects: 232
Study 25955224 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (20 μg/kg/d)
Number of subjects: 66
Study 25955224 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (200 μg/d)
Number of subjects: 66
Study 25955224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogens and oral contraceptive pills (30 μg of ethinyl estradiol plus 150 μg of desogestrel) and 4 mg/d of estradiol valerate
Number of subjects: 66
Study 25955224 — intervention group
Group type: COMPARATOR
Intervention: Nonprimed cycles
Number of subjects: 66
Study 23104720 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab-based chemotherapy (ATBC)
Number of subjects: 276
Study 23104720 — intervention group
Group type: COMPARATOR
Intervention: No treatment (ATBC-)
Number of subjects: 276
Study 23104720 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 276
Study 23104720 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab alone
Number of subjects: 276
Study 21430611 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping plus exercise
Number of subjects: 39
Study 21430611 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping alone
Number of subjects: 39
Study 21430611 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 39
Study 18478463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracolonic drainage (biofragmentable anastomosis ring and condom)
Number of subjects: 119
Study 18478463 — intervention group
Group type: COMPARATOR
Intervention: Protective ileostomy
Number of subjects: 119
Study 17140167 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg/day)
Number of subjects: 10
Study 17140167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14572567 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Fr bipolar electrocoagulation catheter
Number of subjects: 77
Study 14572567 — intervention group
Group type: COMPARATOR
Intervention: 7-Fr bipolar electrocoagulation catheter
Number of subjects: 77
Study 14572567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (10-Fr and 7-Fr)
Number of subjects: 77
Study 10771457 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 25
Study 10771457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8835044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 6
Study 8835044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1425625 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 1 mg
Number of subjects: 580
Study 1425625 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 580
Study 1425625 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 580
Study 1425625 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 580
Study 6372428 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement group (balanced protein-calorie beverage)
Number of subjects: 0
Study 6372428 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement group (high-protein beverage)
Number of subjects: 0
Study 6372428 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine vitamin and mineral tablets)
Number of subjects: 0
Study 31846643 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation followed by esophagectomy
Number of subjects: 7691
Study 31846643 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive surgical margins
Number of subjects: 7691
Study 31846643 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility surgical volume
Number of subjects: 7691
Study 31846643 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission within 30 days
Number of subjects: 7691
Study 31846643 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally-invasive surgery converted to open
Number of subjects: 7691
Study 31846643 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 69 and older
Number of subjects: 7691
Study 31846643 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagectomy more than 45 days from completion of chemoradiation
Number of subjects: 7691
Study 30067578 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 77
Study 26702788 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Vapour Product (EVP)
Number of subjects: 0
Study 26702788 — intervention group
Group type: COMPARATOR
Intervention: Nicorette(®)
Number of subjects: 0
Study 26702788 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cigarette (CC)
Number of subjects: 0
Study 24499763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation
Number of subjects: 73
Study 24499763 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation
Number of subjects: 73
Study 23029839 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional airway nerve blocks (whole airway block including bilateral superior laryngeal nerve block, bilateral glossopharyngeal block, and recurrent laryngeal nerve block)
Number of subjects: 100
Study 23029839 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 100
Study 20102879 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (p-PCI)
Number of subjects: 1037
Study 20102879 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose tenecteplase before PCI (f-PCI)
Number of subjects: 1037
Study 17350556 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sided appeals
Number of subjects: 263
Study 17350556 — intervention group
Group type: COMPARATOR
Intervention: 1-sided appeals
Number of subjects: 263
Study 17350556 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal arguments
Number of subjects: 263
Study 17350556 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritative arguments
Number of subjects: 263
Study 16333795 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous anticoagulation therapy (INR 2.0 - 3.0) in patients with AF and LA thrombi
Number of subjects: 32
Study 16333795 — intervention group
Group type: COMPARATOR
Intervention: Control group with equivalent anticoagulation regimen (no LA thrombi)
Number of subjects: 32
Study 12668861 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (specifically abciximab)
Number of subjects: 0
Study 12668861 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 12668861 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridines and glycoprotein (GP) IIb/IIIa inhibitors
Number of subjects: 0
Study 12668861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9809953 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (8 microg/kg infused over 1 h)
Number of subjects: 20
Study 9809953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9809953 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum (PNO)
Number of subjects: 20
Study 7649753 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic discharge screens indicating absence of documentation of discharge planning
Number of subjects: 20136
Study 7649753 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic discharge screens indicating elevated temperature
Number of subjects: 20136
Study 7649753 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic discharge screens indicating abnormal pulse
Number of subjects: 20136
Study 7649753 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic discharge screens indicating unaddressed abnormal test results at discharge
Number of subjects: 20136
Study 7649753 — intervention group
Group type: COMPARATOR
Intervention: Generic discharge screens indicating abnormal blood pressure
Number of subjects: 20136
Study 7649753 — intervention group
Group type: COMPARATOR
Intervention: Generic discharge screens indicating IV fluids or drugs
Number of subjects: 20136
Study 7649753 — intervention group
Group type: COMPARATOR
Intervention: Generic discharge screens indicating wound drainage before discharge
Number of subjects: 20136
Study 2664523 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily)
Number of subjects: 33
Study 2664523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31005964 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation for 6 months
Number of subjects: 1673
Study 29382477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day preparation with PEG 3350 (4 g/kg/day) + bisacodyl
Number of subjects: 0
Study 29382477 — intervention group
Group type: COMPARATOR
Intervention: 2 days preparation with PEG 3350 (2 g/kg/day) + bisacodyl
Number of subjects: 0
Study 25557052 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 7
Study 22784101 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 26
Study 22784101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22011917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S)
Number of subjects: 100
Study 22011917 — intervention group
Group type: COMPARATOR
Intervention: Propofol (group P)
Number of subjects: 100
Study 18690586 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention (3 telephone calls at intervals of 2 months)
Number of subjects: 175
Study 16825685 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-deficient diet for up to 42 days
Number of subjects: 51
Study 16825685 — intervention group
Group type: COMPARATOR
Intervention: Control diet (recommended adequate intake of choline) for 10 days
Number of subjects: 51
Study 14633553 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 34
Study 14633553 — intervention group
Group type: COMPARATOR
Intervention: Standard management (control)
Number of subjects: 34
Study 11141242 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV/SQV
Number of subjects: 26
Study 11141242 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV/SQV/d4T
Number of subjects: 26
Study 11141242 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT/3TC/abacavir/nevirapine/indinavir
Number of subjects: 26
Study 11141242 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26
Study 9364884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulisation of Salbutamol
Number of subjects: 120
Study 9364884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulisation of Ipratropium bromide
Number of subjects: 120
Study 9364884 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline nebulisation
Number of subjects: 120
Study 9364884 — intervention group
Group type: COMPARATOR
Intervention: Humidified oxygen without nebulisation
Number of subjects: 120
Study 1337206 — intervention group
Group type: EXPERIMENTAL
Intervention: diethyldithiocarbamate
Number of subjects: 29
Study 1337206 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 2882771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Number of subjects: 6
Study 2882771 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6
Study 2882771 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 6
Study 2882771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 6
Study 2882771 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 6
Study 30326711 — intervention group
Group type: EXPERIMENTAL
Intervention: e-book intervention
Number of subjects: 65
Study 30326711 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 65
Study 25611183 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum drops
Number of subjects: 30
Study 25611183 — intervention group
Group type: COMPARATOR
Intervention: Conventional artificial tears
Number of subjects: 30
Study 24548289 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flatulogenic test diet (n = 15)
Number of subjects: 30
Study 24548289 — intervention group
Group type: COMPARATOR
Intervention: Balanced control diet (Mediterranean type) (n = 15)
Number of subjects: 30
Study 23090524 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone and 800 micrograms buccal misoprostol
Number of subjects: 729
Study 20216098 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated food allergy patients
Number of subjects: 0
Study 20216098 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with food allergy and celiac disease
Number of subjects: 0
Study 20216098 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 18594529 — intervention group
Group type: EXPERIMENTAL
Intervention: VAPEC-B+G-CSF
Number of subjects: 80
Study 18594529 — intervention group
Group type: COMPARATOR
Intervention: VAPEC-B
Number of subjects: 80
Study 16144532 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 12043955 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-based intranasal triamcinolone acetonide formulation (Tri-Nasal) at doses of 100, 200, and 400 microg over 7 days
Number of subjects: 0
Study 12043955 — intervention group
Group type: COMPARATOR
Intervention: Aqueous suspension-based triamcinolone acetonide formulation (Nasacort AQ) at doses of 110, 220, and 440 microg
Number of subjects: 0
Study 10421591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg PO) for 4 weeks
Number of subjects: 20
Study 10421591 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20
Study 10421591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg PO)
Number of subjects: 20
Study 7547842 — intervention group
Group type: EXPERIMENTAL
Intervention: [15N]yoghurt
Number of subjects: 16
Study 7547842 — intervention group
Group type: EXPERIMENTAL
Intervention: [15N]milk
Number of subjects: 16
Study 7547842 — intervention group
Group type: EXPERIMENTAL
Intervention: [15N]milk and [15N]yoghurt
Number of subjects: 16
Study 2291597 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 47
Study 2291597 — intervention group
Group type: COMPARATOR
Intervention: Metopimazine
Number of subjects: 47
Study 7303757 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorton and Imuran
Number of subjects: 36
Study 7303757 — intervention group
Group type: COMPARATOR
Intervention: Encorton
Number of subjects: 36
Study 31182181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index, low insulin index (LGI-LII) meal
Number of subjects: 15
Study 27832514 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with BAY 81-8973
Number of subjects: 0
Study 27832514 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment with BAY 81-8973
Number of subjects: 0